Baillie Gifford & Co. Has $48.51 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Baillie Gifford & Co. decreased its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 19.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 984,302 shares of the company's stock after selling 243,226 shares during the period. Baillie Gifford & Co. owned about 1.69% of Twist Bioscience worth $48,506,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at $30,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Twist Bioscience by 31.3% during the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company's stock worth $113,000 after acquiring an additional 546 shares in the last quarter. CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company's stock valued at $120,000 after purchasing an additional 524 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Twist Bioscience during the 1st quarter valued at approximately $124,000.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the firm's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the transaction, the insider now directly owns 78,996 shares of the company's stock, valued at $3,154,310.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the firm's stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $28,310.37. Following the transaction, the insider now directly owns 78,996 shares in the company, valued at approximately $3,154,310.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Patrick John Finn sold 2,207 shares of the company's stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the sale, the chief operating officer now owns 171,212 shares of the company's stock, valued at approximately $9,694,023.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,327 shares of company stock valued at $978,760. Company insiders own 3.92% of the company's stock.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded up $1.20 on Friday, reaching $43.66. 613,430 shares of the company's stock were exchanged, compared to its average volume of 1,019,082. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90. The firm's 50-day moving average is $49.58 and its two-hundred day moving average is $42.41.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company's revenue for the quarter was up 27.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.01) earnings per share. On average, equities analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a report on Monday, August 5th. TD Cowen raised their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, June 13th. Guggenheim began coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a "buy" rating and a $53.00 target price on the stock. Evercore ISI lifted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday, May 3rd. Finally, The Goldman Sachs Group increased their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $48.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.